Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

179 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial.
Ychou M, Rivoire M, Thezenas S, Quenet F, Delpero JR, Rebischung C, Letoublon C, Guimbaud R, Francois E, Ducreux M, Desseigne F, Fabre JM, Assenat E. Ychou M, et al. Among authors: assenat e. Ann Surg Oncol. 2013 Dec;20(13):4289-97. doi: 10.1245/s10434-013-3217-x. Epub 2013 Aug 17. Ann Surg Oncol. 2013. PMID: 23955585 Clinical Trial.
[Portal vein embolization: Present and future].
Piron L, Deshayes E, Escal L, Souche R, Herrero A, Pierredon-Foulongne MA, Assenat E, le Lam N, Quenet F, Guiu B. Piron L, et al. Among authors: assenat e. Bull Cancer. 2017 May;104(5):407-416. doi: 10.1016/j.bulcan.2017.03.009. Epub 2017 May 3. Bull Cancer. 2017. PMID: 28477870 Review. French.
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.
Rimassa L, Assenat E, Peck-Radosavljevic M, Pracht M, Zagonel V, Mathurin P, Rota Caremoli E, Porta C, Daniele B, Bolondi L, Mazzaferro V, Harris W, Damjanov N, Pastorelli D, Reig M, Knox J, Negri F, Trojan J, López López C, Personeni N, Decaens T, Dupuy M, Sieghart W, Abbadessa G, Schwartz B, Lamar M, Goldberg T, Shuster D, Santoro A, Bruix J. Rimassa L, et al. Among authors: assenat e. Lancet Oncol. 2018 May;19(5):682-693. doi: 10.1016/S1470-2045(18)30146-3. Epub 2018 Apr 3. Lancet Oncol. 2018. PMID: 29625879 Clinical Trial.
Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapy.
Mazard T, Assenat E, Dupuy M, Mollevi C, René A, Adenis A, Chauffert B, Boucher E, Francois E, Pierga JY, Ducreux M, Ychou M, Gallix B. Mazard T, et al. Among authors: assenat e. Dig Liver Dis. 2019 Aug;51(8):1185-1191. doi: 10.1016/j.dld.2019.03.028. Epub 2019 May 10. Dig Liver Dis. 2019. PMID: 31085108 Clinical Trial.
Outcome after pancreatectomy for neuroendocrine neoplams according to the WHO 2017 grading system: A retrospective multicentric analysis of 138 consecutive patients.
Souche R, Coignac A, Dupuy M, Bertrand M, Raingeart I, Guiu B, Herrero A, Panaro F, Obled S, Portales F, Riviere B, Ramos J, Borie F, Quenet F, Colombo PE, Prudhomme M, Assenat E, Fabre JM; Renaten Languedoc-Roussillon Study Group; Réseau de référence clinique pour les tumeurs endocrines malignes sporadiques et héréditaires. Souche R, et al. Among authors: assenat e. Clin Res Hepatol Gastroenterol. 2020 Jun;44(3):286-294. doi: 10.1016/j.clinre.2019.08.010. Epub 2019 Sep 19. Clin Res Hepatol Gastroenterol. 2020. PMID: 31543336
179 results